{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:01:01Z","timestamp":1788998461992,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"am","delay-in-days":301,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA195586"],"award-info":[{"award-number":["R01 CA195586"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA247471"],"award-info":[{"award-number":["R01 CA247471"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA200466"],"award-info":[{"award-number":["U01 CA200466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA210240"],"award-info":[{"award-number":["U01 CA210240"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA213862"],"award-info":[{"award-number":["U01 CA213862"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.canlet.2022.215801","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T17:24:09Z","timestamp":1655659449000},"page":"215801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer"],"prefix":"10.1016","volume":"544","author":[{"given":"Shailendra K.","family":"Gautam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasrinivasa R.","family":"Sajja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suprit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi V.","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayana","family":"Rachagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-3687","authenticated-orcid":false,"given":"Maneesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib1","first-page":"7","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1215-3","article-title":"Pancreatic cancer: challenges and opportunities","volume":"16","author":"Zhu","year":"2018","journal-title":"BMC Med."},{"issue":"7","key":"10.1016\/j.canlet.2022.215801_bib3","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1053\/j.gastro.2019.01.259","article-title":"Early detection of pancreatic cancer: opportunities and challenges","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.canlet.2022.215801_bib4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.2174\/092986732522180704091601","article-title":"Pancreatic cancer chemoprevention: challenges and opportunities","volume":"25","author":"Mohammed","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pan.2014.10.001","article-title":"Addressing the challenges of pancreatic cancer: future directions for improving outcomes","volume":"15","author":"Hidalgo","year":"2015","journal-title":"Pancreatology : Off. J. Int. Assoc. Pancreatol."},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2022.215801_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib9","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/jpet.118.255786","article-title":"Combination therapies and drug delivery platforms in combating pancreatic cancer","volume":"370","author":"Lei","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ags3.12225","article-title":"Role of the tumor microenvironment in pancreatic cancer","volume":"3","author":"Murakami","year":"2019","journal-title":"Ann. Gastroenterol. Surg."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.05.012","article-title":"Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer","volume":"178","author":"Ligorio","year":"2019","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.canlet.2022.215801_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: diagnostic and therapeutic implications","volume":"9","author":"Erkan","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.canlet.2022.215801_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.255","article-title":"Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going","volume":"49","author":"Liang","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2022.215801_bib14","series-title":"Mapping Physical Tumor Microenvironment and Drug Delivery","author":"Nia","year":"2019"},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.trecan.2018.02.010","article-title":"Reengineering the tumor vasculature: improving drug delivery and efficacy","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41598-018-37909-5","article-title":"Pancreatic adenocarcinomas with mature blood vessels have better overall survival","volume":"9","author":"Katsuta","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-2-8","article-title":"Pathways for aberrant angiogenesis in pancreatic cancer","volume":"2","author":"Korc","year":"2003","journal-title":"Mol. Cancer"},{"issue":"46","key":"10.1016\/j.canlet.2022.215801_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"17","key":"10.1016\/j.canlet.2022.215801_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201902746","article-title":"MT1-MMP-Activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy","volume":"7","author":"Wei","year":"2020","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2022.215801_bib21","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.canlet.2022.215801_bib24","first-page":"1675","article-title":"Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors","volume":"7","author":"Dey","year":"2015","journal-title":"Am. J. Tourism Res."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1440-1681.1999.03014.x","article-title":"Endothelins in health and disease: an overview","volume":"26","author":"Goldie","year":"1999","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc990","article-title":"The endothelin axis: emerging role in cancer","volume":"3","author":"Nelson","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.critrevonc.2013.08.011","article-title":"A review of the profile of endothelin axis in cancer and its management","volume":"89","author":"Irani","year":"2014","journal-title":"Crit. Rev. Oncol.-Hematol."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s13277-011-0299-6","article-title":"Targeting the endothelin axis in prostate carcinoma","volume":"33","author":"Pinto","year":"2012","journal-title":"Tumor Biol."},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jclinpath-2014-202521","article-title":"Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma","volume":"68","author":"Cook","year":"2015","journal-title":"J. Clin. Pathol."},{"issue":"13","key":"10.1016\/j.canlet.2022.215801_bib30","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/onc.2013.109","article-title":"Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells","volume":"33","author":"Wu","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2013.784","article-title":"Endothelin B receptor expression correlates with tumour angiogenesis and prognosis in oesophageal squamous cell carcinoma","volume":"110","author":"Tanaka","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)64791-8","article-title":"Role of endothelin-1 in neovascularization of ovarian carcinoma","volume":"157","author":"Salani","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-002-0534-3","article-title":"Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor","volume":"51","author":"Rai","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.canlet.2022.215801_bib34","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-03-1291","article-title":"Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment","volume":"64","author":"Sonveaux","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2022.215801_bib35","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1535-7163.MCT-05-0472","article-title":"Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery","volume":"5","author":"Martinive","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10620-008-0366-z","article-title":"Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells","volume":"54","author":"Fitzner","year":"2009","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neo.2019.11.001","article-title":"Irreversible and sustained upregulation of endothelin axis during oncogene-associated pancreatic inflammation and cancer","volume":"22","author":"Gupta","year":"2020","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ijc.2910250507","article-title":"Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma","volume":"25","author":"Morgan","year":"1980","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2022.215801_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-62703-287-2_11","article-title":"Development of orthotopic pancreatic tumor mouse models","volume":"980","author":"Qiu","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib40","article-title":"Modeling pancreatic cancer in mice for experimental therapeutics","volume":"1876","author":"Mallya","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2022.215801_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-316","article-title":"DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data","volume":"14","author":"Ortu\u00f1o","year":"2013","journal-title":"BMC Bioinf."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11523-010-0135-8","article-title":"Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy","volume":"5","author":"Padhani","year":"2010","journal-title":"Targeted Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178002","article-title":"Perfusion MR imaging detection of carcinoma arising from preexisting salivary gland pleomorphic adenoma by computer-assisted analysis of time-signal intensity maps","volume":"12","author":"Katayama","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1148\/rg.271065078","article-title":"Functional MR imaging of prostate cancer","volume":"27","author":"Choi","year":"2007","journal-title":"Radiographics : Rev. Pub. Radiol. Soc. North Am."},{"issue":"12","key":"10.1016\/j.canlet.2022.215801_bib45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4329\/wjr.v9.i12.416","article-title":"Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: a review of current methods and applications","volume":"9","author":"Mazaheri","year":"2017","journal-title":"World J. Radiol."},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib46","first-page":"1008","article-title":"Role of host Microenvironment in Angiogenesis and microvascular Functions in human breast cancer xenografts: mammary fat pad <strong><em>versus<\/em><\/strong> cranial tumors","volume":"8","author":"Monsky","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ymeth.2005.11.007","article-title":"Western blotting","volume":"38","author":"Kurien","year":"2006","journal-title":"Methods"},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193907","article-title":"Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer","volume":"13","author":"Aithal","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.canlet.2016.02.016","article-title":"Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological implication(s) for early diagnosis of colon cancer","volume":"374","author":"Krishn","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41388-020-01518-2","article-title":"Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma","volume":"40","author":"Nimmakayala","year":"2021","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1746-1596-7-42","article-title":"Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring","volume":"7","author":"Rizzardi","year":"2012","journal-title":"Diagn. Pathol."},{"issue":"8","key":"10.1016\/j.canlet.2022.215801_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.canlet.2022.215801_bib53","first-page":"6036","article-title":"Chromosome 7 suppresses indefinite division of nontumorigenic immortalized human fibroblast cell lines KMST-6 and SUSM-1","volume":"13","author":"Ogata","year":"1993","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0958-1669(99)00011-7","article-title":"Constructing immortalized human cell lines","volume":"10","author":"Yeager","year":"1999","journal-title":"Curr. Opin. Biotechnol."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-014-3072-x","article-title":"Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: are signal intensity-time curves adequate?","volume":"147","author":"Woolf","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib56","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s00261-016-1024-0","article-title":"Correlation between quantitative and semiquantitative parameters in DCE-MRI with a blood pool agent in rectal cancer: can semiquantitative parameters be used as a surrogate for quantitative parameters?","volume":"42","author":"Dijkhoff","year":"2017","journal-title":"Abdom. Radiol."},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"issue":"15","key":"10.1016\/j.canlet.2022.215801_bib58","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin. Cancer Res. : Off. J. Am. Asoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-020-01787-5","article-title":"Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine","volume":"40","author":"Yu","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/labinvest.2017.127","article-title":"Experimental models of pancreatic cancer desmoplasia","volume":"98","author":"Suklabaidya","year":"2018","journal-title":"Lab. Invest."},{"issue":"7","key":"10.1016\/j.canlet.2022.215801_bib61","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034793","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy","volume":"11","author":"Erstad","year":"2018","journal-title":"Dis. Model. Mech."},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2016.09.012","article-title":"Vascular mimicry formation is promoted by paracrine TGF-\u03b2 and SDF1 of cancer-associated fibroblasts and inhibited by miR-101 in hepatocellular carcinoma","volume":"383","author":"Yang","year":"2016","journal-title":"Cancer Lett."},{"issue":"25","key":"10.1016\/j.canlet.2022.215801_bib64","doi-asserted-by":"crossref","first-page":"8413","DOI":"10.1074\/jbc.RA119.011748","article-title":"Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer","volume":"295","author":"Khan","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.canlet.2022.215801_bib65","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.034793","article-title":"Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy","volume":"11","author":"Erstad","year":"2018","journal-title":"Dis. Model. Mech."},{"issue":"70","key":"10.1016\/j.canlet.2022.215801_bib66","article-title":"Impact of cancer-associated fibroblast on the radiation-response of solid xenograft tumors","volume":"6","author":"Steer","year":"2019","journal-title":"Front. Mol. Biosci."},{"issue":"20","key":"10.1016\/j.canlet.2022.215801_bib67","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","article-title":"Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis","volume":"79","author":"Mizutani","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib68","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jamcollsurg.2014.07.311","article-title":"MicroRNAs in pancreatic fibroblast induced by tumor cells","volume":"219","author":"Nguyen","year":"2014","journal-title":"J. Am. Coll. Surg."},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib69","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tranon.2016.07.004","article-title":"Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma","volume":"9","author":"Kumar","year":"2016","journal-title":"Transl. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2022.215801_bib70","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1073\/pnas.1525349113","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages","volume":"113","author":"Peterson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.canlet.2022.215801_bib71","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival","volume":"113","author":"Kloepper","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.canlet.2022.215801_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141392","article-title":"Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages","volume":"10","author":"Incio","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.canlet.2022.215801_bib73","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.canlet.2022.215801_bib74","doi-asserted-by":"crossref","first-page":"E3769","DOI":"10.1073\/pnas.1722434115","article-title":"Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk","volume":"115","author":"Orozco","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"7","key":"10.1016\/j.canlet.2022.215801_bib75","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-007-9589-5","article-title":"Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion","volume":"108","author":"Smollich","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030824","article-title":"Endothelin receptor antagonists: status quo and future perspectives for targeted therapy","volume":"9","author":"Enevoldsen","year":"2020","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.canlet.2022.215801_bib78","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/labinvest.3780357","article-title":"Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation","volume":"81","author":"Tsuzuki","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2022.215801_bib79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2017.12.017","article-title":"BQ123 selectively improved tumor perfusion and enhanced nanomedicine delivery for glioblastomas treatment","volume":"132","author":"Zhang","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib80","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-005-9000-3","article-title":"Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats","volume":"94","author":"Rajeshkumar","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib81","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.gassur.2004.11.007","article-title":"Selective inhibition of endothelin receptor A as an anti-angiogenic and anti-proliferative strategy for human pancreatic cancer","volume":"9","author":"Bhargava","year":"2005","journal-title":"J. Gastrointest. Surg."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib82","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/07853890410018925","article-title":"Role of endothelin in fibrosis and anti-fibrotic potential of bosentan","volume":"37","author":"Clozel","year":"2005","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib83","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1186\/ar4529","article-title":"Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1","volume":"16","author":"Akamata","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.canlet.2022.215801_bib84","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI118925","article-title":"Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing","volume":"98","author":"Rockey","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10620-008-0366-z","article-title":"Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells","volume":"54","author":"Fitzner","year":"2009","journal-title":"Dig. Dis. Sci."},{"issue":"609","key":"10.1016\/j.canlet.2022.215801_bib86","article-title":"Targeting endothelin-1 receptor\/\u03b2-arrestin-1 Axis in ovarian cancer: from basic research to a therapeutic approach","volume":"10","author":"Tocci","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.canlet.2022.215801_bib87","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ijc.26090","article-title":"Endothelin-1 stimulates colon cancer adjacent fibroblasts","volume":"130","author":"Knowles","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"13\u201314","key":"10.1016\/j.canlet.2022.215801_bib88","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.lfs.2012.04.001","article-title":"Endothelin-1 stimulates oral fibroblasts to promote oral cancer invasion","volume":"91","author":"Hinsley","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2022.215801_bib89","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618823440","article-title":"Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience","volume":"13","author":"Belge","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"12","key":"10.1016\/j.canlet.2022.215801_bib90","first-page":"2464","article-title":"Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study","volume":"33","author":"Allanore","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.canlet.2022.215801_bib91","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1476-4598-9-69","article-title":"A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy","volume":"9","author":"Kefford","year":"2010","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2022.215801_bib92","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10637-006-9014-7","article-title":"A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma","volume":"25","author":"Kefford","year":"2007","journal-title":"Invest. N. Drugs"},{"issue":"9","key":"10.1016\/j.canlet.2022.215801_bib93","article-title":"Endothelin inhibition potentiates cancer immunotherapy revealing mechanical biomarkers predictive of response","volume":"4","author":"Voutouri","year":"2021","journal-title":"Adv. Therapeut."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib94","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bbrc.2020.04.118","article-title":"Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells","volume":"527","author":"Ahn","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2022.215801_bib95","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/mrm.24218","article-title":"In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology","volume":"69","author":"Lemasson","year":"2013","journal-title":"Magn. Reson. Med."},{"issue":"2","key":"10.1016\/j.canlet.2022.215801_bib96","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/1522-2594(200008)44:2<224::AID-MRM9>3.0.CO;2-M","article-title":"MR imaging of microvasculature","volume":"44","author":"Jensen","year":"2000","journal-title":"Magn. Reson. Med."},{"issue":"4","key":"10.1016\/j.canlet.2022.215801_bib97","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI73455","article-title":"Transport properties of pancreatic cancer describe gemcitabine delivery and response","volume":"124","author":"Koay","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.canlet.2022.215801_bib98","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3899\/jrheum.131284","article-title":"Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis","volume":"41","author":"Cutolo","year":"2014","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.canlet.2022.215801_bib99","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3899\/jrheum.100358","article-title":"Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension","volume":"37","author":"Rosato","year":"2010","journal-title":"J. Rheumatol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522002853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522002853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:04:13Z","timestamp":1759593853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522002853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":99,"alternative-id":["S0304383522002853"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215801","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"215801"}}